Duphaston

PreclinicalSmall molecule

Merck & Co.

Duphaston is one of 49 small molecule programs targeting Endometriosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndometriosisActive, not recruiting

Gnrh AntagonistTerminated

EndometriosisPreclinical

Active, not recruiting

Gnrh AntagonistPreclinical

Terminated

Competition

Competitive Landscape

60 competitors in Endometriosis

#DrugCompanyPhaseTrials

Danocrine

Sanofi

Approved

5 2

Bayer Aspirin

Bayer

Approved

2 3

Orilissa

AbbVie

Phase 3

16 4

IC-Green

PProvepharm SAS

Approved

4 5

Estrace

Novo Nordisk

Approved

—6

Ketalar

AAultman Health Foundation

Approved

2 7

Flagyl

DDePuy Orthopaedics

Approved

1 8

Zocor

OOrganon and Co

Approved

1 9

Implanon

OOrganon and Co

Approved

1 10

Trelstar

OOncoVerity, Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

GnRH Antagonist3 trials

Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders

Completed·—·Phase 3·NCT04537078·90 enrolled

Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF

Terminated·SShangHai Ji Ai Genetics & IVF Institute·N/A·NCT03680053·220 enrolled

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A

Completed·SShangHai Ji Ai Genetics & IVF Institute·Phase 3·NCT04414748·400 enrolled

Efficacy and Safety2 trials

Comparative Study to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Estradiol / Dydrogesterone in Perimenopausal Women

Unknown status·SScientific Research Institute of Public Health, Russian Federation·Phase 4·NCT05156814·150 enrolled

Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)

Terminated· Merck & Co. logo

Merck & Co.·Phase 4·NCT03858049·172 enrolled

Frozen Embryo Transfer1 trial

The Rescue of Hormonal Replacement Frozen Embryo Transfer Cycle With Low Serum Progesterone.

Unknown status·—·Phase 2/3·NCT05758064·120 enrolled

Pregnancy1 trial

Predictors of Pregnancy Rate in Assisted Reproductive Technology According to Actual Guidelines

Unknown status·AAbbott··NCT04249297·1,150 enrolled

Endometriosis1 trial

Study of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis

Completed·AAbbott··NCT03690765·350 enrolled

1 more indication

Ovarian Stimulation1 trial

Luteal Phase Ovarian Stimulation With Follitropin Delta and Dydrogesterone

Unknown status·CCRG UZ Brussel·N/A·NCT05521828·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Duphaston. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Duphaston compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Duphaston. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Merck & Co.

Duphaston

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

GnRH Antagonist3 trials

Efficacy and Safety2 trials

Frozen Embryo Transfer1 trial

Pregnancy1 trial

Endometriosis1 trial

Ovarian Stimulation1 trial

References

Drug Info

Quick Facts

Related News